Separable Cell Cycle Arrest and Immune Response Elicited through Pharmacological CDK4/6 and MEK Inhibition in RASmut Disease Models.

Abstract excerpt

The combination of CDK4/6 and MEK inhibition as a therapeutic strategy has shown promise in various cancer models, particularly in those harboring RAS mutations. An initial high-throughput drug screen identified high synergy between the CDK4/6 inhibitor palbociclib and the MEK inhibitor trametinib when used in combination in soft tissue sarcomas. In RAS mutant models, combination treatment with palbociclib and...

Topics

Join the communities discussing this publication.

• Cell Cycle Checkpoints
• Cyclin-Dependent Kinase 4
• Cyclin-Dependent Kinase 6
• Piperazines
• Pyridines